bromoacetoxy-calcidiol

B3CD is a **3-bromoacetoxy-ester derivative** of calcidiol (25-hydroxyvitamin D3), developed as a potential non-calcemic anti-cancer agent. In vitro, B3CD exhibits cell line-specific cytotoxicity and antiproliferative effects, particularly against ovarian cancer cells (notably SKOV-3), as well as certain prostate, pancreatic, neuroblastoma, and endothelial cell lines. Mechanistically, B3CD induces cell death via activation of the p38 MAPK signaling pathway and promotes apoptosis, with evidence of chromatin condensation and nuclear fragmentation in sensitive cancer cell lines. In vivo, B3CD has shown efficacy in delaying tumor growth and occasionally producing complete tumor regression in mouse xenograft models of ovarian cancer, without inducing significant toxicity or hypercalcemia at effective doses. The compound is under investigation primarily as an experimental anti-cancer therapeutic, especially for platinum-resistant ovarian cancer, and has been proposed for further development targeting MAPK-mediated cell death pathways[1].

Other names

bromoacetoxy-calcidiol